CORDIS
EU research results

CORDIS

English EN
Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma

Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma

Objective

The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans.
We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Address

6 Christou Lada Str
10561 Athina

Greece

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 353 750

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 1 128 000

SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS

Switzerland

EU Contribution

€ 287 500

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 222 500

UNIVERSYTET MEDYCZNY W LODZI.

Poland

EU Contribution

€ 232 500

UMEA UNIVERSITET

Sweden

EU Contribution

€ 217 500

GIORGI ELIAVA INSTITUTE OF BACTERIOPHAGY, MICROBIOLOGY AND VIROLOGY

Georgia

EU Contribution

€ 222 500

ELIAVA BIO PREPARATIONS LTD

Georgia

EU Contribution

€ 60 000

EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING

Belgium

EU Contribution

€ 112 500

MARIOS LYMARAKIS KAI SIA EE

Greece

EU Contribution

€ 135 000

Project information

Grant agreement ID: 767015

Status

Ongoing project

  • Start date

    1 October 2017

  • End date

    30 September 2021

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 2 971 750

  • EU contribution

    € 2 971 750

Coordinated by:

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece